Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: GlobeNewswire
SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) a clinical stage development company based in San Diego and focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Hendrick Scholl, Chief Medical Officer, will present at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference (dbVIC) on April 28th, 2026. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors. Details of the presentation are as follows: DATE: April 28th TIME: 9:00 a.m. ET REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the onlin
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Belite Bio (BLTE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.MarketBeat
- Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt DiseaseGlobeNewswire
- Foundation Fighting Blindness to Host United in Vision 2026 Conference in Partnership with Retina International World CongressPR Newswire
- Belite Bio (BLTE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.MarketBeat
- Belite Bio (BLTE) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
BLTE
Earnings
- 3/2/26 - Beat
BLTE
Sec Filings
- 4/22/26 - Form 4
- 4/21/26 - Form 4
- 4/21/26 - Form 6-K
- BLTE's page on the SEC website